Zegbeh Jallah
Stock Analyst at Capital One
(3.00)
# 1,460
Out of 4,735 analysts
26
Total ratings
34.78%
Success rate
111.08%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Zegbeh Jallah
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| OTLK Outlook Therapeutics | Upgrades: Overweight | $100 | $2.30 | +4,257.30% | 2 | Dec 27, 2023 | |
| GLYC GlycoMimetics | Initiates: Overweight | $12 | $0.26 | +4,464.47% | 1 | Dec 22, 2023 | |
| EYPT EyePoint Pharmaceuticals | Initiates: Overweight | $44 | $7.63 | +476.67% | 1 | Dec 11, 2023 | |
| KOD Kodiak Sciences | Upgrades: Overweight | n/a | $7.50 | - | 5 | Nov 17, 2023 | |
| IDYA IDEAYA Biosciences | Initiates: Overweight | $29 | $23.15 | +25.27% | 2 | Dec 28, 2022 | |
| RAPT RAPT Therapeutics | Initiates: Overweight | $48 | $1.20 | +3,900.00% | 2 | Sep 21, 2022 | |
| ENTA Enanta Pharmaceuticals | Maintains: Buy | $101 → $70 | $5.12 | +1,267.19% | 2 | May 12, 2022 | |
| SYRS Syros Pharmaceuticals | Maintains: Buy | $200 → $230 | $0.21 | +109,947.85% | 1 | Sep 23, 2021 | |
| RZLT Rezolute | Initiates: Buy | $21 | $4.92 | +326.83% | 1 | Sep 8, 2021 | |
| ARVN Arvinas | Maintains: Buy | $120 → $135 | $18.57 | +626.98% | 2 | Aug 9, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $108 → $132 | $3.33 | +3,863.96% | 1 | Jun 30, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $10 → $6 | $0.75 | +700.32% | 2 | Jun 11, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $55 | $8.75 | +528.57% | 1 | Feb 18, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | n/a | $2.17 | - | 1 | Aug 5, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $0.92 | +767.58% | 1 | May 13, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $20 | $0.49 | +3,987.47% | 1 | Dec 18, 2019 |
Outlook Therapeutics
Dec 27, 2023
Upgrades: Overweight
Price Target: $100
Current: $2.30
Upside: +4,257.30%
GlycoMimetics
Dec 22, 2023
Initiates: Overweight
Price Target: $12
Current: $0.26
Upside: +4,464.47%
EyePoint Pharmaceuticals
Dec 11, 2023
Initiates: Overweight
Price Target: $44
Current: $7.63
Upside: +476.67%
Kodiak Sciences
Nov 17, 2023
Upgrades: Overweight
Price Target: n/a
Current: $7.50
Upside: -
IDEAYA Biosciences
Dec 28, 2022
Initiates: Overweight
Price Target: $29
Current: $23.15
Upside: +25.27%
RAPT Therapeutics
Sep 21, 2022
Initiates: Overweight
Price Target: $48
Current: $1.20
Upside: +3,900.00%
Enanta Pharmaceuticals
May 12, 2022
Maintains: Buy
Price Target: $101 → $70
Current: $5.12
Upside: +1,267.19%
Syros Pharmaceuticals
Sep 23, 2021
Maintains: Buy
Price Target: $200 → $230
Current: $0.21
Upside: +109,947.85%
Rezolute
Sep 8, 2021
Initiates: Buy
Price Target: $21
Current: $4.92
Upside: +326.83%
Arvinas
Aug 9, 2021
Maintains: Buy
Price Target: $120 → $135
Current: $18.57
Upside: +626.98%
Jun 30, 2021
Maintains: Buy
Price Target: $108 → $132
Current: $3.33
Upside: +3,863.96%
Jun 11, 2021
Downgrades: Neutral
Price Target: $10 → $6
Current: $0.75
Upside: +700.32%
Feb 18, 2021
Maintains: Buy
Price Target: $30 → $55
Current: $8.75
Upside: +528.57%
Aug 5, 2020
Initiates: Buy
Price Target: n/a
Current: $2.17
Upside: -
May 13, 2020
Initiates: Buy
Price Target: $8
Current: $0.92
Upside: +767.58%
Dec 18, 2019
Initiates: Buy
Price Target: $20
Current: $0.49
Upside: +3,987.47%